Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

SAN DIEGO, Sept. 24, 2026 // -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of c…